10x Genomics (TXG) Cash & Equivalents (2018 - 2026)

10x Genomics has disclosed Cash & Equivalents across 9 years of filings, most recently posting $502.5 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 26.35% year-over-year to $502.5 million; the TTM figure through Jun 2026 stood at $502.5 million (up 26.35% YoY), while the FY2025 annual figure was $474.0 million, up 37.75% from the prior year.
• Cash & Equivalents came in at $502.5 million for Q2 2026 at 10x Genomics, up from $490.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $502.5 million in Q2 2026 to a low of $219.7 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $362.3 million, with a median of $357.5 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 62.59% in 2022 and jumped 63.5% in 2023.
• Over 5 years, Cash & Equivalents stood at $219.7 million in 2022, then soared by 63.5% to $359.3 million in 2023, then fell by 4.24% to $344.1 million in 2024, then jumped by 37.75% to $474.0 million in 2025, then grew by 6.02% to $502.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $502.5 million in Q2 2026, $490.3 million in Q1 2026, and $474.0 million in Q4 2025.